Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "BioPharmaDive" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about BioPharmaDive for you to read. Along with our medical data and news we also list BioPharmaDive Clinical Trials, which are updated daily. BioPortfolio also has a large database of BioPharmaDive Companies for you to search.
Already approved in Europe, Vitaros didn't gain favor with U.S. regulators, who found CMC and safety issues with the erectile dysfunction drug.
A relatively large research collaboration could change the deal landscape. Elsewhere, the Alzheimer's development picture is getting a makeover.
Acquiring the tech unicorn will help Roche better use real-world evidence in the development of cancer drugs, while building its data analytics expertise.
In new guidance to industry, the regulator signaled greater flexibility around the use of biomarkers in studying the neurodegenerative disease.
As a result of the warning letter, the German giant expects a temporary effect on the supply of certain mature products.
Acquiring MPI Research should raise Charles Rivers' profits as early as this year and expand its business with biotech.
Company executives insisted the pre-planned check did not change their confidence in aducanumab, which has become Biogen's key pipeline asset.
The duo's checkpoint inhibitor Bavencio failed to beat out chemotherapy in the key setting of non-small cell lung cancer.
The spinoff-turned-Sanofi-company could pay more than $100 million to Oxford BioMedica for lentiviral vector production.
The biologics specialist plans to add 100 jobs by 2020 to staff the new center, which will focus on supporting Phase 1 clinical trials.
Eight years on from its first U.S. clinical trial, DBV Technologies' immunotherapy patch to combat peanut allergy could be submitted for U.S. approval in the second half of 2018.
The FDA greenlighted apalutamide for non-metastatic CRPC based on a new endpoint: metastasis-free survival.
In the highly competitive IL-inhibitor space, securing new indications has been a key strategy for drugmakers looking to gain an edge.
The trade body for generics and biosimilar manufacturers warns of barriers to entry for its products.
The big pharma discontinued another trial, acknowledging its drug doesn't work in early patients.
The analysis comes as a new Senate report calls into question drugmaker ties to advocacy groups in fighting the epidemic.
The Irish pharma faces headwinds in immunology, neuroscience and blood disorders, and its unclear whether new product launches can offset them.
It's a substantial upfront sum to gain access to Nektar's early-stage candidate, reflecting the growing importance of building an edge in combination immunotherapy.
The CEO says he wouldn't change a thing, despite the high-profile failure and sharp decline of the company.
Symdeko, a combination treatment for cystic fibrosis, holds a price tag of $292,000 and could provide Vertex up to $200 million in revenue by year's end.
U.S. approval of Novartis' version of Copaxone 40 mg came earlier than Teva had assumed, putting further pressure on the Israeli drugmaker's top seller.
The administration's budget includes a proposal to prevent generic drugmakers from abusing the current system.
Three emerging trends that are shaping society and the pharmaceutical industry create a convincing argument for the use of softgel technology.
The Boston biotech's latest deal builds up its internal pipeline and gives troubled drug bavituximab another shot at success.
While Roivant has programs in endocrinology, the licensing pact for imeglimin pulls the Swiss biotech into the diabetes arena.